Sweet smell of success for patients taking the sugar pill

15 January 2019 - A placebo is anything that seems to offer a real medical treatment, but doesn’t. It could ...

Read more →

Challenges of non-intention-to-treat analyses

15 January 2019 - Over the past 5 decades, the randomised clinical trial has become the gold standard for evaluation ...

Read more →

Establishing the effectiveness of procedural interventions: the limited role of randomised trials

18 December 2018 - Procedural interventions comprise a large and growing component of medical care. Patients, physicians, health care organisations, and ...

Read more →

Metastasis-free survival in prostate cancer: faster drug approvals, better drugs?

12 December 2018 - On 13 February 2018, the US FDA granted marketing authorisation to apalutamide for treatment of non-metastatic castration-resistant ...

Read more →

Australia's first telehealth cancer drug trial

3 December 2018 - A partnership between north Queensland hospitals is bringing potentially life-saving cancer drug trials to rural patients. ...

Read more →

The evolution of adaptiveness: balancing speed and evidence

29 November 2018 - 'Adaptive' approaches to bringing drugs to market have been widely discussed in recent years.  ...

Read more →

Lung cancer survivor wants PHARMAC to fund drugs she received in trial

22 October 2018 - Lung cancer patient Marjolein Baas takes the drug ceritinib, one of six lung cancer treatment drugs the ...

Read more →

Congratulations. Your study went nowhere.

23 September 2018 - Researchers should embrace negative results instead of accentuating the positive, which is one of several biases that ...

Read more →

CDER conversation: complex innovative trial designs

25 September 2018 - Complex innovative trial designs – including the use of adaptive, Bayesian, and other novel statistical approaches ...

Read more →

Cost of clinical trials for new drug FDA approval are fraction of total tab

24 September 2018 - Clinical trials that support FDA approvals of new drugs have a median cost of $19 million, ...

Read more →

FDA proposes stiff fines for failing to report clinical trials

20 September 2018 - Pharmaceutical companies could face penalties of up to US$10,000 per day. ...

Read more →

Using evidence from randomised controlled trials in economic models: what information is relevant and is there a minimum amount of sample data required to make decisions?

21 September 2018 - Evidence from randomised controlled trials is used to support regulatory approval and reimbursement decisions.  ...

Read more →

Harvard Professor's attack on pharma's clinical trials is absurd

18 September 2018 - Dr. Marcia Angell, a senior lecturer at Harvard Medical School and the first woman to serve as ...

Read more →

Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource

12 September 2018 - Following the 2012 EC guideline, sponsors must ensure that all trials registered on EUCTR since 2004 disclose ...

Read more →

Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

31 August 2018 - Several trials in cancer medicine over the past 5 years share two common features: first, they were ...

Read more →